Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01756417 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT01756417: Completed Phase 1 study of Healthy, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

NCT01756417 is a Phase 1 study of Healthy that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 18 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01756417, a Phase 1 study of Healthy, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate whether there is a drug-drug interaction between multiple doses of canagliflozin (JNJ-28431754) and a single dose of metformin. The safety and tolerability of canagliflozin will also be assessed.

Primary Outcome

Cmax (a measure of the body's exposure to canagliflozin \[JNJ-28431754\]) will be compared before and after administration of a single dose of metformin.

Conditions Studied

Interventions

  • DRUG Metformin
  • DRUG Canagliflozin (JNJ-28431754)

Study Locations (1)

New Jersey

  • - Neptune City

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2007-10
Est. Completion 2007-11
Phase Phase 1

What the finished NCT01756417 record still lists

NCT01756417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.

NCT01756417 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT01756417 about?

NCT01756417 is a clinical study titled "A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers". The purpose of this study is to investigate whether there is a drug-drug interaction between multiple doses of canagliflozin (JNJ-28431754) and a single dose of metformin. The safety and tolerability of canagliflozin will also be assessed.

What is the current status of trial NCT01756417?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-10. Estimated completion is 2007-11.

What conditions does trial NCT01756417 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01756417?

The interventions under investigation include: Metformin (DRUG), Canagliflozin (JNJ-28431754) (DRUG).

Who is sponsoring clinical trial NCT01756417?

This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01756417 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01756417's enrollment target sits among peer trials

18 904th of 1090 higher than 163 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01756417, the US trial registry maintained by the National Library of Medicine. NCT01756417 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.